PPT-MGUS and Smoldering Myeloma:

Risk stratification and Therapeutic Options Natalie S Callander MD University of Wisconsin Carbone Cancer Center 1 MGUS definition 2 Factors associated with MGUS progression 3 Appropriate evaluation. T: J. Ohlemiller Introduction Smoldering is a slow, low-temperature, flameless form of combustion, sustained by the heat evolved when oxygen directly attacks the surface of a condensed-phase fuel. Sm Paul Moss. Birmingham, UK. Outline. Introduction to immunotherapy. Immunotherapy in the setting of Myeloma . Cellular therapy. Future application. History of Cancer Therapy. Surgery. 1000s of years. Radiotherapy. NICE Guideline. Published Feb 2016. Adults with myeloma (and plasma cell leukaemia). Excluded:. Monoclonal . gammopathy. of uncertain significance (MGUS). Amyloidosis. Solitary . plasmacytomas. Included:. Presented By Sham Mailankody at 2016 ASCO Annual Meeting. Massive genetic heterogeneity in <br />multiple myeloma. Presented By Sham Mailankody at 2016 ASCO Annual Meeting. Multiple myeloma consistently preceded by precursor states. new treatment in the horizon. Dr Amin . I. slam . MB, MRCP UK , FRCPath UK. Consultant haematologist and . H. aemato. -Oncologist. Southend University Hospital NHS Foundation trust. Myeloma patients support group meeting. Mike Chapman. University of Cambridge Department of Haematology. Novel agents have improved survival. What is a biomarker?. “A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”. Smoldering Myeloma: To Treat or not to Treat Ruben Niesvizky MD Myeloma Center Myelomacenter.org run9001@med.cornell.edu CASE A 47-year-old man is diagnosed with smoldering multiple myeloma . He has cyclin. and PI3k pathways. UKMF Spring meeting 2015. Kwee Yong, UCL Cancer Institute. Not one, but many myelomas. Dysregulation. of D-type . cyclin. in multiple myeloma. Early oncogenic events . dysregulate. Vi Dao, MD, FRCPC. vdao@cancercare.mb.ca. Presenter Disclosure. Faculty: Vi Dao. Relationships with commercial interests: none. Mitigating Potential Bias. Not Applicable. Learning Objectives. Distinguish MGUS from multiple myeloma. Can we do better?. [Hospital name]. [Date]. What is myeloma?. Cancer of plasma cells. Leads to:. Bone infiltration. - fractures (especially vertebral wedge fractures), hypercalcaemia. - pain. Professor Mark Drayson, University of Birmingham. 13. th. March 2019. Distinguishing myeloma from MGUS by m-protein and serum free light chain results alone. M. yeloma . is the worst cancer for delayed diagnosis . H . Nèji. , H . Abid. , A . Mâalej. , S . Haddar. , R . Akrout. *, . M . Ezzeddine. *, S . Baklouti. *, . Z . Mnif. **, J . Mnif. Imaging department . Habib. . Bourguiba. Hospital, . *Rheumatology department . Aric Hall, MD. Assistant Professor – UW Health. Objectives . To discuss pathophysiology of plasma cell disorders. To define and describe the asymptomatic plasma cell dyscrasias. To discuss prognosis. Presenter Disclosure. Faculty: Mark Kristjanson. Relationships with commercial interests: none. Mitigating Potential Bias. Not Applicable. Learning Objectives. List the indications for SPEP & FLC.